RZLT

Rezolute, Inc.

1.56 USD
-0.16 (-9.30%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rezolute, Inc. stock is up 41.82% since 30 days ago. The next earnings date is May 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 10 February’s closed higher than January. 100% of analysts rate it a buy.

About Rezolute, Inc.

Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.